Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Weak
GARP
Very Weak
MQV Small
Neutral
Momentum
Price
Very Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Weak
Quality
Capital Efficiency
Neutral
Balance Sheet
Very Weak
Website
N/ATelephone
N/A
Address
Suite 2, Level 11 385 Bourke Street Melbourne, Victoria (VIC) 3205
Description
Lumos Diagnostics Holdings Ltd. engages in the development and manufacture of point-of-care diagnostics solutions to help healthcare professionals more accurately diagnose and manage medical conditions. It manages the provision of diagnostics goods and services. It operates through the United States and Australia geographical segments. The company was founded in 2015 and is headquartered in South Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.02 - 0.19
Trade Value (12mth)
AU$55,540.00
1 week
25%
1 month
59.09%
YTD
360.53%
1 year
430.3%
All time high
1.31
EPS 3 yr Growth
-96.20%
EBITDA Margin
0.00%
Operating Cashflow
$0m
Free Cash Flow Return
0.00%
ROIC
0.00%
Interest Coverage
N/A
Quick Ratio
0.00
Shares on Issue (Fully Dilluted)
N/A
HALO Sector
Healthcare
Next Company Report Date
02-Sep-26
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
15 September 25 |
Application for quotation of securities - LDX
×
Application for quotation of securities - LDX |
15 September 25 |
Section 708A Cleansing Statement
×
Section 708A Cleansing Statement |
11 September 25 |
Application for quotation of securities - LDX
×
Application for quotation of securities - LDX |
11 September 25 |
Section 708A Cleansing Statement
×
Section 708A Cleansing Statement |
09 September 25 |
Lumos Completes A$5.0 million Loan Facility
×
Lumos Completes A$5.0 million Loan Facility |
09 September 25 |
Lumos Signs Second ANZ FebriDx Distribution Agreement
×
Lumos Signs Second ANZ FebriDx Distribution Agreement |
08 September 25 |
Notification regarding unquoted securities - LDX
×
Notification regarding unquoted securities - LDX |
04 September 25 |
Application for quotation of securities - LDX
×
Application for quotation of securities - LDX |
04 September 25 |
Section 708A Cleansing Statement
×
Section 708A Cleansing Statement |
02 September 25 |
Application for quotation of securities - LDX
×
Application for quotation of securities - LDX |
02 September 25 |
Section 708A Cleansing Statement
×
Section 708A Cleansing Statement |
02 September 25 |
FY25 Results Investor Briefing Presentation
×
FY25 Results Investor Briefing Presentation |
01 September 25 |
LDX & BARDA partner on new US$6.2m FebriDx Paediatric Study
×
LDX & BARDA partner on new US$6.2m FebriDx Paediatric Study |
01 September 25 |
Lumos secures follow-on PKU contract with Aptatek
×
Lumos secures follow-on PKU contract with Aptatek |
28 August 25 |
FY25 Appendix 4E
×
FY25 Appendix 4E |
28 August 25 |
FY25 Annual Report
×
FY25 Annual Report |
28 August 25 |
Appendix 4G and Corporate Governance
×
Appendix 4G and Corporate Governance |
26 August 25 |
FY25 Results - Investor Briefing Invitation
×
FY25 Results - Investor Briefing Invitation |
26 August 25 |
Application for quotation of securities - LDX
×
Application for quotation of securities - LDX |
26 August 25 |
Section 708A Cleansing Statement and Excluded Information
×
Section 708A Cleansing Statement and Excluded Information |
18 August 25 |
Lumos Announces FebriDx CLIA Waiver Application Submission
×
Lumos Announces FebriDx CLIA Waiver Application Submission |
14 August 25 |
Lumos Partners with PRO-spectus for FebriDx Market Access
×
Lumos Partners with PRO-spectus for FebriDx Market Access |
13 August 25 |
Waiver of ASX Listing Rule 10.1 Granted
×
Waiver of ASX Listing Rule 10.1 Granted |
21 July 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
21 July 25 |
Q4 FY25 Results Investor Briefing
×
Q4 FY25 Results Investor Briefing |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.